Abexinostat

Abexinostat (PCI-24781) is a small-molecule drug developed by Xynomic Pharmaceuticals. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: Abexinostat tosylate salt is formulated into an oral tablet formulation and is available in 20 mg strength. It is the investigational product in 5 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT03592472 (A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)), in renal cell carcinoma, diffuse large B-cell lymphoma, follicular lymphoma and hodgkin lymphoma. The largest, NCT03592472, plans to enrol 413 participants with primary completion expected 2026-12-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.